Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Kodak CEO's fortune swells $79 million as stocks rally on U.S. government loan

Published 07/29/2020, 06:42 PM
Updated 07/29/2020, 06:45 PM
© Reuters. A worker cleans a Kodak booth at the Las Vegas Convention Center in preparation for 2019 CES in Las Vegas

By Jessica DiNapoli

(Reuters) - Eastman Kodak Co (N:KODK) CEO Jim Continenza added $79 million to his net worth on Wednesday when his options in the imaging company turned from worthless to lucrative thanks to a U.S. government loan for a pharmaceutical ingredients supply deal that super-charged the value of his shares.

Kodak's stock increased 1,167% in value in two days, after the administration of President Donald Trump agreed to provide a $765 million loan for the company to produce pharmaceutical ingredients to help fight the coronavirus pandemic. Trump announced the deal at a news conference on Tuesday evening.

Continenza's stock options, granted to him when he became Kodak's CEO and executive chairman in 2019, had no value on Monday, but were worth $59 million on Wednesday following the rally in the stock, according to an analysis by compensation consultant Farient Advisors. Continenza also owned 650,000 Kodak shares as of June 23, which went up in value on the news by $20 million.

Kodak did not immediately respond to a request for comment.

Before news of the deal, Kodak, which emerged from bankruptcy in 2013, was only worth a little over $100 million. It ended trading on Wednesday with a market capitalization of $1.5 billion.

While Kodak's rally enriched all its shareholders, more than half the company is owned by a few key insiders, including board directors Philippe Katz and George Karfunkel. They booked the majority of the gains in the company's rise in market value.

Rochester, New York-based Kodak, founded in 1888, is best known for its cameras, which went out of favor with consumers as they turned to smart phones to take pictures. Kodak was also known for its film and film processing, businesses that dried up with the growth of digital photography.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

This was not the first example of a U.S. government contract quickly enriching corporate executives. Stock options awarded to executives at U.S. vaccine maker Novavax Inc (O:NVAX) swelled in value after a $1.6 billion grant from the federal government last month.

Latest comments

sad? Trump just made one of the most important moves for our future well being. How could you not celebrate this? Oh cause some poor executives had windfall luck, probably backed up by some hard work making this happen. BTW who said you can't buy some shares? This company will definitely be one of the best investments over the next 10 years. Pull the trigger instead of cry over your unsubstantiated hatred for USA
Yes, keep licking that boot.
Sad.......
Gotta love the government stealing your money in plain sight. Who in the Trump family bought shares last week?
Definitely a lot of insider trading going on in the Trump adminstration.
I hope they all did and you to. I got mine
Criminal
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.